Inflammatory substances released by mast cells induce and maintain the allergic response 1, 2 . Mast cell differentiation and activation are regulated, respectively, by stem cell factor (SCF; also known as Kit ligand) and by allergen in complex with allergen-specific immunoglobulin E (IgE) 2, 3 . Activated SCF receptors and high-affinity receptors for IgE (Fc1RI) engage phosphoinositide 3-kinases (PI(3)Ks) to generate intracellular lipid second messenger signals [2] [3] [4] [5] . Here, we report that genetic or pharmacological inactivation of the p110d isoform of PI(3)K in mast cells leads to defective SCF-mediated in vitro proliferation, adhesion and migration, and to impaired allergen-IgE-induced degranulation and cytokine release. Inactivation of p110d protects mice against anaphylactic allergic responses. These results identify p110d as a new target for therapeutic intervention in allergy and mast-cell-related pathologies.
PI (3)Ks activated by the Fc1RI and SCF receptors include the heterodimeric class IA PI(3)Ks, which consist of a p110a, p110b or p110d catalytic subunit bound to either one of five regulatory proteins (p85a, p55a, p50a, p85b or p55g) that link the p110 subunits to tyrosine kinase signalling pathways 6 . Mast cells express high levels of the p110d isoform 7 which, unlike the ubiquitously expressed p110a and p110b, is primarily found in leukocytes 8, 9 . Whereas mice lacking p110a or p110b are embryonic lethal 6 , p110d-null mice are viable, with specific defects in B and T cells 10 . To investigate the role of p110d in mast cells, we derived bone marrow mast cells (BMMCs) from mice expressing either wild-type p110d or p110d D910A , a loss-of-function allele of p110d (ref. 11). Culture of bone marrow precursor cells from both genotypes in the presence of interleukin-3 (IL-3) gave rise to mature BMMCs, which expressed identical levels of Fc1RI and Kit receptor (as assessed by fluorescence-activated cell sorting analysis; data not shown) and were morphologically indistinguishable (as assessed by alcian blue and safranin staining; data not shown). However, the number of BMMCs obtained from p110d D910A/D910A cultures was substantially lower (up to 60%; data not shown). Similar observations were made when precursor cells were cultured in the presence of IL-3 plus SCF, giving rise to up to 50% less BMMCs in p110d mutant cells (data not shown).
The level of class I PI(3)K isoform expression in p110d
BMMCs is similar to that of wild-type cells (Fig. 1a) . p110d lipid Figure 1 Effect of p110d inactivation on PI(3)K expression and activity. . letters to nature kinase activity was abrogated in p110d D910A/D910A BMMCs, with no alterations in the kinase activities of p110a and p110b (Fig. 1b) . Total in vitro class IA PI(3)K lipid kinase activity, isolated from mutant BMMCs, was reduced by up to 90% (Fig. 1c) , indicating that p110d contributes substantially to the overall class IA PI(3)K activity in mast cells. In agreement with this, there was no increase in in vivo phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) above resting levels in p110d D910A/D910A cells upon stimulation with SCF (Fig. 1d) .
To assess the impact of p110d inactivation on intracellular signalling, we monitored Ser 473 phosphorylation of protein kinase B (PKB, also known as Akt) and Tyr 204 phosphorylation of Erk as indirect measures of activation of these kinases. SCF-induced PKB phosphorylation was almost completely abrogated in p110d D910A/D910A BMMCs, in contrast with Erk activation, which was not affected (Fig. 2a) . These results could be mimicked in wild-type cells by the p110d-selective inhibitor IC87114 (ref. 12) (Fig. 2c, d ). It has been reported 12 that IC87114 is selective for p110d in cells at doses up to 5-10 mM; this is in line with our observation that such doses of this compound do not affect cells in which p110d is already genetically inactivated (data not shown and Figs 2f and 3c). IL-3-induced PKB phosphorylation was severely reduced but not completely abrogated in mutant mast cells (Fig. 2b ). IL-3-stimulated PKB phosphorylation could be completely blocked by treatment with LY294002, a broad-spectrum PI(3)K inhibitor ( Fig. 2e and ref. 13 ), indicating that isoforms other than p110d contribute to PI(3)K signalling downstream of the IL-3 receptor. The residual IL-3-induced PI(3)K activity in p110d D910A/D910A cells may explain why mature BMMCs can be derived from p110d D910A/D910A bone marrow precursors in the presence of this cytokine. As was seen for SCF, IL-3-induced Erk activation was not affected by inactivation of p110d (Fig. 2b) , and pharmacological inhibition of p110d using IC87114 on wild-type cells mirrored the impact of genetic inactivation of p110d on IL-3 signalling (Fig. 2e) .
We next assessed in vitro functional responses of p110d D910A/ D910A mast cells to SCF or IL-3. DNA synthesis induced by each cytokine was severely reduced (Fig. 2f , left and middle panels). The synergistic effect on DNA synthesis of co-stimulation with IL-3 and SCF was also substantially diminished in p110d D910A/D910A BMMCs (Fig. 2f , right panel). Treatment with IC87114 reduced DNA synthesis of wild-type BMMCs without significantly affecting p110d D910A/D910A BMMCs (Fig. 2f) . Other SCF-stimulated responses that were severely decreased in p110d D910A/D910A mast cells include the ability to adhere to fibronectin upon SCF stimulation ( Fig. 2g ) and migration towards SCF (Fig. 2h) . Taken together, these data indicate a critical contribution of p110d in signalling of SCF towards physiological functions of this cytokine such as proliferation, stimulation of adhesion to the extracellular matrix and chemotactic activity for homing of mast cells to tissues 14 . We next compared the capacity of BMMCs from p110d . Data in f-h are expressed as mean^s.d.
letters to nature and wild-type mice to respond to antigen in complex with IgE. Such complexes aggregate the Fc1RI on mast cells, initiating biochemical signalling cascades that ultimately lead to the release of inflammatory mediators, cytokines and to much of the pathology associated with the allergic response 1, 2, 4 . Ser 473 phosphorylation of PKB induced by Fc1RI activation was substantially reduced in p110d D910A/D910A BMMCs (Fig. 3a) . We also tested the capacity of cultured mast cells to release contents from intracellular stores into the surrounding environment upon stimulation with antigen/allergen via the Fc1RI receptor. As a read-out, we measured release of b-hexosaminidase, an enzyme stored in mast cell granules 15 . Inclusion of 30 mM of LY294002, a broad-spectrum PI(3)K inhibitor, reduced the degranulation of wild-type mast cells by ,80% (Fig. 3b, left panel) , confirming that PI(3)K is a significant component of the signalling cascade leading to mast cell degranulation 15, 16 . p110d D910A/D910A BMMCs showed a 45-55% reduction in Fc1RI-induced degranulation, relative to wild-type cells (Fig. 3b,  left panel) . Similar results were obtained when the cells were incubated with IgE overnight, washed and then stimulated with antigen (Ag), with degranulation defects observed across a wide dose range of antigen (Fig. 3b, right panel) . Degranulation in p110d D910A/D910A BMMCs could be further reduced by LY294002, as in wild-type cells (left panel of Fig. 3b ). Pre-incubation of wildtype mast cells with 5 mM IC87114 reduced degranulation levels to those seen in p110d D910A/D910A cells while having no effect on p110d mutant cells (Fig. 3c) . IC87114 inhibited degranulation to the same extent in human mast cells (Fig. 3d) and also blocked the capacity of SCF to potentiate degranulation by low doses of antigen (Fig. 3e) . The observation that p110d is critical for the SCF component of mast cell degranulation is of particular physiological relevance, given that mast cells are continuously exposed to SCF in the local tissue environment. Mast cell activation thus occurs in the context of SCF signalling, especially during inflammatory response with excessive local production of SCF 17, 18 . p110d D910A/D910A BMMCs also showed defects in secretion of inflammatory cytokines such as TNF-a and IL-6 (Fig. 3f) . Overall, these data indicate that p110d is the main component of the PI(3)K-dependent antigen-IgE signalling cascade leading to degranulation, and is essential for the SCF-mediated potentiation of Fc1RI activity.
In p110d D910A/D910A mice mast cell numbers were differentially affected in distinct anatomical locations (Supplementary Table 1) , with defects ranging from severe (peritoneum, jejunum, ileum and colon) to moderate (ear dermis (Fig. 4a) , stomach submucosa and muscularis) to no significant differences (back dermis (Fig. 4a) , mucosa of the stomach). A decrease in mast cell numbers is in line with a critical role of SCF in mast cell differentiation and survival, and the importance of p110d in signalling by this cytokine. The residual mast cells present in p110d D910A/D910A mice may result from SCF signalling pathways unaffected by p110d inactivation (such as the Erk pathway) and/or from developmental/homeostatic cues other than SCF.
We next investigated the impact of p110d inactivation on allergic responses in the mouse. In vivo anaphylaxis through the Fc1RI receptor is an allergic response that is predominantly mast-celldependent and occurs as a result of either local or systemic exposure to allergens, which crosslink and activate antigen-specific IgE bound to the Fc1RI on the mast cell surface. We assessed the capacity of wild-type and p110d D910A/D910A mice to respond to immune challenge in a passive cutaneous anaphylaxis (PCA) model 19 . Mice were given an intradermal injection of IgE directed against a hapten (dinitrophenyl (DNP) in this case). Between 24-48 h after this priming event the mice were challenged by systemic administration of DNP coupled to a carrier protein (HSA) together with Evan's blue dye, which binds to serum proteins. Mediators released upon mast cell activation increase vascular permeability, which allows the dye to leak from the blood vessels into the surrounding tissue, causing oedema and providing a measure of mast cell activation. We assessed the PCA response in two distinct tissue locations. In the ear of p110d D910A/D910A mice, a marked (80%) reduction in PCA was observed (Fig. 4b) . This decrease is more significant than the letters to nature reduction in mast cell numbers at this location (maximally 47%; Supplementary Table 1 ), suggesting that the remaining mutant mast cells may be defective. PCA in the back dermis-a site with unaltered mast cell numbers in p110d D910A/D910A mice (Supplementary Table 1 ; Fig. 4a )-was also significantly reduced (40%; Fig. 4c) . IC87114, at pharmacological doses at which it is selective for p110d (plasma concentration of 5 mM from a 15 mg kg 21 dose), reduced the allergic response by 35-40% in the back skin and ear of wildtype mice (Fig. 4d ; data for the ear are not shown). At higher plasma concentrations (40 mM from a 60 mg kg 21 dose) IC87114 completely blocked the anaphylaxis reaction in the back dermis (Fig. 4d) .
This may be a consequence of the inhibition of other PI(3)K isoforms (such as p110g), which could account for the remaining PI(3)K-dependent (that is, LY294002-sensitive) degranulation seen in p110d D910A/D910A BMMCs (Fig. 3b, left panel) . These data show that this class of small molecule inhibitors of PI(3)K can completely abrogate in vivo cutaneous anaphylaxis.
Taken together, our data show that the p110d PI(3)K isoform has an important role in mast cell homeostasis and in the allergic response. Our observations are in contrast with studies in mice lacking regulatory subunits of class IA PI(3)Ks, which indicated that class IA PI(3)K enzymes are not involved in IL-3 and Fc1RI-mediated allergic responses 7, 15, 16, 20 . The reason for this discrepancy is not clear, but may relate to the complex impact of loss of expression of class IA PI(3)K regulatory subunits on the class IA PI(3)K system, with increased expression of the remaining regulatory subunits and reduced expression of all p110 isoforms, and even increased PI(3)K signalling under certain circumstances [21] [22] [23] [24] [25] . This contrasts with the present study, in which p110d was selectively inactivated by introduction of a point mutation in the ATP-binding site, mimicking the effect of a systemically administered ATPcompetitive p110d inhibitor. Indeed, in vivo administration of a p110d-selective inhibitor reproduced the therapeutic effect of the D910A mutation in the context of anaphylaxis. Interference with PI(3)K signalling pathways is being explored as a means of therapeutic intervention in many different pathological conditions 26 . Our work suggests a promising therapeutic potential for p110d-selective compounds to treat allergy and other pathological conditions in which mast cells have a central role.
A
Methods
Mice p110d D910A/D910A mice have been described previously 11 and were backcrossed on a C57BL/6 or BALB/c background for 6-10 generations. Age-matched, 6-10-week-old littermate mice were used for all experiments.
Mast cell cultures
Total bone marrow samples from the femurs of 3-5 mice were cultured in RPMI medium supplemented with 10% ultra-low IgG FBS (Gibco), 10 ng ml 21 IL-3 (Tebu-bio), 20 ng ml 21 SCF (Tebu-bio), 2 mM L-glutamine, 100 U ml 21 penicillin and streptomycin (Gibco) in a 5% CO 2 atmosphere. After a 4-week maturation period, BMMCs were collected and tested for c-kit receptor and Fc1RI expression by flow cytometry using phycoerythrin-labelled rat anti-c-kit (Pharmingen) or anti-DNP IgE (SPE-7; Sigma) and monoclonal fluorescein isothiocyanate-anti-mouse IgE (Molecular Probes) antibodies, respectively. BMMCs used for this study were cultured with IL-3 and SCF, unless otherwise indicated, with culture times not exceeding 6 weeks.
Cytokine stimulation, lysis and immunoblotting
Cells were starved for 24 h in normal culture medium lacking IL-3 and SCF. After stimulation with 20 ng ml 21 IL-3 and/or 20 ng ml 21 SCF, the cells were washed twice with ice-cold PBS, lysed and processed for immunoblotting and kinase assays as described 11 .
Lipid kinase assay
In vitro lipid kinase assays were carried out as previously described 11 (see Supplementary Information for further details). In vivo levels of PIP 3 were determined by a time-resolved fluorescence resonance energy transfer ligand displacement assay, as described 27 . 
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Degranulation and cytokine secretion
Degranulation experiments were carried out in triplicate in 96-well plates. Exponentially growing cells were stimulated with IgE-antigen complex for 60 min. Degranulation is expressed as a percentage of total b-hexosaminidase activity in the input cells (see Supplementary Information for detailed methods) . Cytokine released into the supernatants was assessed using Quantikine kits (R&D Systems).
Human mast cell studies
Human mast cells were obtained by culture of peripheral blood CD34 þ cells in Stem Pro 34 media (Invitrogen) containing recombinant human IL-3 (30 ng ml 21 ), IL-6 (100 ng ml
21
) and SCF (100 ng ml 21 ) (Pepro Tech) for 1 week, followed by culture without IL-3 (but with IL-6 and SCF as above) for a further 6-7 weeks as described 28 (see Supplementary  Information for detailed methods) . . letters to nature
